alexa Henipavirus Vaccine Development | OMICS International | Abstract
ISSN: 2157-2526

Journal of Bioterrorism & Biodefense
Open Access

Like us on:

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Review Article

Henipavirus Vaccine Development

Jackie Pallister1*, Deborah Middleton1, Christopher C. Broder2 and Lin-Fa Wang1

1CSIRO Livestock Industries, Australian Animal Health Laboratory, 5 Portarlington Road, Geelong, VIC, 3220, Australia

2Department of Microbiology and Immunology, Uniformed Services University, Bethesda, MD 20814, USA

*Corresponding Author:
Jackie Pallister
CSIRO Livestock Industries
Australian Animal Health Laboratory
5 Portarlington Road,Geelong
VIC, 3220, Australia
Tel: 61 3 5227 5277
Fax: 61 3 52275555
E-mail: [email protected]

Received Date: July 16, 2010; Accepted Date: September 07, 2011; Published Date: September 25, 2011

Citation: Pallister J, Middleton D, Broder CC, Wang LF (2011) Henipavirus Vaccine Development. J Bioterr Biodef S1:005. doi: 10.4172/2157-2526.S1-005

Copyright: © 2011 Pallister J, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.


The henipaviruses, Hendra virus and Nipah virus, belong to the family Paramyxoviridae which has long been a source of highly contagious pathogens for both humans and animals. Some notable paramyxoviruses such as measles virus have spilled over from animals into humans to cause significant morbidity and mortality. Since 1994 the henipaviruses have periodically emerged from their animal reservoir in flying foxes to cause disease in human and animal populations. The recent emergence of these viruses coupled with the high mortality rate associated with henipavirus infections and the lack of any licensed prophylactic or therapeutic treatments, makes them agents of particular concern in the area of both human and agricultural biodefense. Advances in our understanding of henipavirus infection and pathogenesis has led to the development of several promising vaccine candidates making it likely that vaccines for henipavirus infections may be available in the near future.